Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.

Multidrug-resistant tuberculosis (MDR-TB) has become a major threat to the control of tuberculosis globally. Uganda is among the countries with a relatively high prevalence of tuberculosis despite significant control efforts. In this study, the drug resistance of Mycobacterium tuberculosis to rifamp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lisa Nkatha Micheni, Kennedy Kassaza, Hellen Kinyi, Ibrahim Ntulume, Joel Bazira
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a2971963218d46a58b6e7f7ad0f25e33
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2971963218d46a58b6e7f7ad0f25e33
record_format	dspace
spelling	oai:doaj.org-article:a2971963218d46a58b6e7f7ad0f25e332021-12-02T20:13:18ZRifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.1932-620310.1371/journal.pone.0259221https://doaj.org/article/a2971963218d46a58b6e7f7ad0f25e332021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259221https://doaj.org/toc/1932-6203Multidrug-resistant tuberculosis (MDR-TB) has become a major threat to the control of tuberculosis globally. Uganda is among the countries with a relatively high prevalence of tuberculosis despite significant control efforts. In this study, the drug resistance of Mycobacterium tuberculosis to rifampicin (RIF) and isoniazid (INH) was investigated among patients diagnosed with pulmonary tuberculosis in Southwestern Uganda. A total of 283 sputum samples (266 from newly diagnosed and 17 from previously treated patients), collected between May 2018 and April 2019 at four different TB diagnostic centres, were assessed for RIF and INH resistance using high-resolution melt curve analysis. The overall prevalence of monoresistance to INH and RIF was 8.5% and 11% respectively, while the prevalence of MDR-TB was 6.7%. Bivariate analysis showed that patients aged 25 to 44 years were at a higher risk of developing MDR-TB (cOR 0.253). Furthermore, among the newly diagnosed patients, the prevalence of monoresistance to INH, RIF and MDR-TB was 8.6%, 10.2% and 6.4% respectively; while among the previously treated cases, these prevalence rates were 5.9%, 23.5% and 11.8%. These rates are higher than those reported previously indicating a rise in MTB drug resistance and may call for measures used to prevent a further rise in drug resistance. There is also a need to conduct frequent drug resistance surveys, to monitor and curtail the development and spread of drug-resistant TB.Lisa Nkatha MicheniKennedy KassazaHellen KinyiIbrahim NtulumeJoel BaziraPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0259221 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lisa Nkatha Micheni Kennedy Kassaza Hellen Kinyi Ibrahim Ntulume Joel Bazira Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
description	Multidrug-resistant tuberculosis (MDR-TB) has become a major threat to the control of tuberculosis globally. Uganda is among the countries with a relatively high prevalence of tuberculosis despite significant control efforts. In this study, the drug resistance of Mycobacterium tuberculosis to rifampicin (RIF) and isoniazid (INH) was investigated among patients diagnosed with pulmonary tuberculosis in Southwestern Uganda. A total of 283 sputum samples (266 from newly diagnosed and 17 from previously treated patients), collected between May 2018 and April 2019 at four different TB diagnostic centres, were assessed for RIF and INH resistance using high-resolution melt curve analysis. The overall prevalence of monoresistance to INH and RIF was 8.5% and 11% respectively, while the prevalence of MDR-TB was 6.7%. Bivariate analysis showed that patients aged 25 to 44 years were at a higher risk of developing MDR-TB (cOR 0.253). Furthermore, among the newly diagnosed patients, the prevalence of monoresistance to INH, RIF and MDR-TB was 8.6%, 10.2% and 6.4% respectively; while among the previously treated cases, these prevalence rates were 5.9%, 23.5% and 11.8%. These rates are higher than those reported previously indicating a rise in MTB drug resistance and may call for measures used to prevent a further rise in drug resistance. There is also a need to conduct frequent drug resistance surveys, to monitor and curtail the development and spread of drug-resistant TB.
format	article
author	Lisa Nkatha Micheni Kennedy Kassaza Hellen Kinyi Ibrahim Ntulume Joel Bazira
author_facet	Lisa Nkatha Micheni Kennedy Kassaza Hellen Kinyi Ibrahim Ntulume Joel Bazira
author_sort	Lisa Nkatha Micheni
title	Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
title_short	Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
title_full	Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
title_fullStr	Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
title_full_unstemmed	Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
title_sort	rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern uganda.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/a2971963218d46a58b6e7f7ad0f25e33
work_keys_str_mv	AT lisankathamicheni rifampicinandisoniaziddrugresistanceamongpatientsdiagnosedwithpulmonarytuberculosisinsouthwesternuganda AT kennedykassaza rifampicinandisoniaziddrugresistanceamongpatientsdiagnosedwithpulmonarytuberculosisinsouthwesternuganda AT hellenkinyi rifampicinandisoniaziddrugresistanceamongpatientsdiagnosedwithpulmonarytuberculosisinsouthwesternuganda AT ibrahimntulume rifampicinandisoniaziddrugresistanceamongpatientsdiagnosedwithpulmonarytuberculosisinsouthwesternuganda AT joelbazira rifampicinandisoniaziddrugresistanceamongpatientsdiagnosedwithpulmonarytuberculosisinsouthwesternuganda
_version_	1718374783348899840

Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.

Ejemplares similares